This "first-pass effect" further reduces the amount of active drug that reaches its target receptors
JAMA Otolaryngol Head Neck Surg 147(12):1100-1106, 2021
However, a recent meta-analysis including eight observational studies revealed increases in cardiovascular and gastrointestinal disorders, and in mortality with regular intake of high therapeutic doses ( Reference Roberts, Delgado Nunes and Buckner 15 )
252 GLP-1 receptor agonists have emerged as an important treatment option for diabetic kidney disease in the context of type 2 diabetes, with semaglutide showing reduced risk of clinically important kidney outcomes and death from cardiovascular causes in people with type 2 diabetes and chronic kidney disease
If your provider prescribed a GLP-1 agonist for you, know that while it can decrease appetite and promote weight loss, your provider may take a comprehensive approach that also includes exercise, diet changes, behavioral modifications, or sometimes even bariatric surgery
Wu ZZ, Ding GF, Huang FF, Yang ZS, Yu FM, Tang YP, et al